DZ Bank raises target for Argenx stock to EUR 935.00

Published on 10/26/2026 at 09:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

argenx posted USD 1.72 billion in third-quarter product sales. Argenx stock costs EUR 785.20 on October 26, 2026, 0.13 percent above the Xetra close.

Analyst view meets pipeline dates

DZ Bank lifted its Argenx fair-value target to EUR 935.00 on October 23, 2026.
Third-quarter product net sales reached USD 1.72 billion in 2026.
Argenx stock trades at EUR 785.20 at 9:37 a.m. CEST at Lang & Schwarz on October 26, 2026, 0.13 percent above the Xetra close of October 23, 2026.
Phase 3 empasiprubart results are expected in December 2026.

Bauhaus-Grafikposter: IgG-Antikörper als geometrisches Y-Symbol in Primärfarben Rot Blau Gelb Schwarz auf weißem Grund, konstruktivistischer Stil der 1920er Jahre — Argenx NL0010832176 IgG-Antikörper als Y-förmiges Bauhaus-Poster in roten blauen und gelben Primärfarben, Illustration mit AI erstellt.

Argenx stock (ISIN NL0010832176) trades at EUR 785.20 at Lang & Schwarz on October 26, 2026 at 9:37 a.m. CEST, 0.13 percent above the Xetra close of October 23, 2026 at EUR 784.20. DZ Bank raised its fair-value target from EUR 861.00 to EUR 935.00 on October 23, 2026.

Third-quarter sales set the tone

argenx reported USD 1.72 billion in product net sales for the third quarter of 2026, up 54.00 percent from the year-earlier period. Total operating income reached USD 1.75 billion, while operating profit rose to USD 486.00 million from USD 346.00 million in the third quarter of 2025, according to MarketScreener.

Three dated steps shape the pipeline

On October 8, 2026, argenx discontinued its Phase 3 UNITY study in Sjogren's disease after the trial was assessed as unlikely to meet its primary endpoint, as reported by Ideal Investisseur. On October 22, 2026, third-quarter product sales reached USD 1.72 billion. On October 23, 2026, DZ Bank lifted its fair-value target to EUR 935.00 from EUR 861.00.

What does the sales growth change?

The commercial engine is expanding, but investment is rising with it. Operating expenses reached USD 1.27 billion in the third quarter of 2026, producing a 28.00 percent operating margin; excluding USD 150.00 million of Forte acquisition-related costs, the margin was 37.00 percent, according to MarketScreener. The company expects combined research and development and selling, general and administrative expenses of USD 4.00 billion for fiscal year 2026.

Pipeline dates now matter

The next milestones are the Phase 3 EMPASSION results for empasiprubart in December 2026 and the FDA decision on pediatric VYVGART indications in February 2027. The company also expects to submit a supplemental application for VYVGART Hytrulo in immune-mediated necrotizing myopathy by the end of 2026, according to MarketScreener.

Stock holds above the Xetra close

The October 26, 2026 quotation places the stock EUR 1.00 above the Xetra close of October 23, 2026. The modest 0.13 percent premium contrasts with the stronger operating figures and leaves upcoming clinical milestones as the next quantified tests for the investment case.

The further course of trading is shown by the continuously updated real-time quote of Argenx stock.